OBJECTIVE: To investigate MRI and proton spectroscopy changes in five patients with HIV associated dementia complex (HADC) treated with antiretroviral therapy. METHODS: Three markers were evaluated: (1) CSF/intracranial volume ratio; (2) T2 weighted signal ratio between parieto-occipital white and subcortical grey matter; and (3) metabolite ratios from long echo time (TE=135 ms) single voxel proton spectra of parieto-occipital white matter. RESULTS: Spectroscopic changes indicated initial increases in N-acetyl/(N-acetyl + choline + creatine) ratio (NA/(NA+ Cho+Cr)) and progression of atrophy after initiation of antiretroviral therapy in four of five patients. When the neurological status of the patients subsequently deteriorated (two of five patients), the NA/(NA+Cho+Cr) ratio also declined. CONCLUSIONS: Spectroscopic changes mirror reversible neuronal dysfunction. These objective, non-invasive techniques may be used for monitoring the neurological effects of antiretroviral drug therapy in patients with HADC.
OBJECTIVE: To investigate MRI and proton spectroscopy changes in five patients with HIV associated dementia complex (HADC) treated with antiretroviral therapy. METHODS: Three markers were evaluated: (1) CSF/intracranial volume ratio; (2) T2 weighted signal ratio between parieto-occipital white and subcortical grey matter; and (3) metabolite ratios from long echo time (TE=135 ms) single voxel proton spectra of parieto-occipital white matter. RESULTS: Spectroscopic changes indicated initial increases in N-acetyl/(N-acetyl + choline + creatine) ratio (NA/(NA+ Cho+Cr)) and progression of atrophy after initiation of antiretroviral therapy in four of five patients. When the neurological status of the patients subsequently deteriorated (two of five patients), the NA/(NA+Cho+Cr) ratio also declined. CONCLUSIONS: Spectroscopic changes mirror reversible neuronal dysfunction. These objective, non-invasive techniques may be used for monitoring the neurological effects of antiretroviral drug therapy in patients with HADC.
Authors: I D Wilkinson; R J Chinn; M A Hall-Craggs; B E Kendall; M N Paley; D L Plummer; R F Miller; M J Harrison Journal: Clin Radiol Date: 1996-07 Impact factor: 2.350
Authors: I D Wilkinson; R F Miller; M N Paley; K A Miszkiel; B E Kendall; M A Hall-Craggs; M J Harrison Journal: AIDS Date: 1996-10 Impact factor: 4.177
Authors: I D Wilkinson; M Paley; W K Chong; B J Sweeney; J K Shepherd; B E Kendall; M A Hall-Craggs; M J Harrison Journal: Magn Reson Imaging Date: 1994 Impact factor: 2.546
Authors: V Tozzi; P Narciso; S Galgani; P Sette; P Balestra; C Gerace; F M Pau; F Pigorini; V Volpini; M P Camporiondo Journal: AIDS Date: 1993-05 Impact factor: 4.177
Authors: M N Paley; W K Chong; I D Wilkinson; J K Shepherd; A M Clews; B J Sweeney; M A Hall-Craggs; B E Kendall; S P Newman; M J Harrison Journal: Radiology Date: 1994-03 Impact factor: 11.105
Authors: M J Harrison; S P Newman; M A Hall-Craggs; C J Fowler; R Miller; B E Kendall; M Paley; I Wilkinson; B Sweeney; S Lunn; S Carter; I Williams Journal: J Neurol Neurosurg Psychiatry Date: 1998-09 Impact factor: 10.154
Authors: Robert H Paul; Thomas Ernst; Adam M Brickman; Constantin T Yiannoutsos; David F Tate; Ronald A Cohen; Bradford A Navia Journal: J Int Neuropsychol Soc Date: 2008-09 Impact factor: 2.892
Authors: Eva-Maria Ratai; Sarah J Pilkenton; Jane B Greco; Margaret R Lentz; Jeffrey P Bombardier; Katherine W Turk; Julian He; Chan-Gyu Joo; Vallent Lee; Susan Westmoreland; Elkan Halpern; Andrew A Lackner; R Gilberto González Journal: BMC Neurosci Date: 2009-06-22 Impact factor: 3.288